Lv5
1440 积分 2022-10-10 加入
Mocertatug rezetecan (GSK5733584), a B7-H4-targeted antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): First results from the global BEHOLD-1 study
1天前
求助中
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
2天前
已完结
Correlation Between Smoking Status and Short-term Outcome of Thoracoscopic Surgery for Lung Cancer
8天前
已关闭
Preoperative Cumulative Smoking Dose on Lung Cancer Surgery in a Japanese Nationwide Database
8天前
已完结
The role of β-tubulin isotypes in resistance to antimitotic drugs
8天前
已完结
New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer
8天前
已完结
Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate
8天前
已完结
Microtubules and resistance to tubulin-binding agents
8天前
已完结
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan, an anti-HER2 antibody-drug conjugate
8天前
已完结
A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
12天前
已完结
皖公网安备34019202002308
